WuXi Biologics (Cayman) Inc. (2269.HK)

77.200 +7.250 (+10.36%) At close: 04:08PM HKT

WuXi Biologics (Cayman) Inc.

No. 108, Meiliang Road
Mashan Binhu District
Wuxi 214092
China

https://www.wuxibiologics.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 9,864

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Ge Li Ph.D.	Founder & Chairman	N/A	N/A	1967
Dr. Zhisheng Chen	CEO & Exec. Director	662.06k	N/A	1973
Dr. Weichang Zhou	Exec. VP, CTO & Exec. Director	354.42k	N/A	1964
Mr. Ming Tu	CFO & Exec. VP	N/A	N/A	1968
Ms. Tang Shaogui M.B.A.	VP and Head of Global Communications, Operations, Marketing & ESG	N/A	N/A	N/A
Dr. Jijie Gu	Exec. VP & Chief Scientific Officer	N/A	N/A	1966
Ms. Eileen Wang	IR Sr. Director	N/A	N/A	N/A
Ms. Cong Ding J.D.	VP & Head of Legal Department	N/A	N/A	N/A
Ms. Li Xiong	VP & Head of Global HR	N/A	N/A	N/A
Mr. Angus Scott Marshall Turner	Sr. VP and Head of Global BD & Alliance Management	N/A	N/A	1968

Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.

Description

WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development and manufacturing in the People's Republic of China, North America, Europe, and internationally. The company also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, and biologics clinical and manufacturing services; production and sale of medicals; vaccine CDMO and related business; and material supplier activities. WuXi Biologics (Cayman) Inc. has strategic partnership with ImmuneOncia Therapeutics, Legochem Biosciences Inc, Worg Pharma, OncoC4, and Exelixis Inc. The company was incorporated in 2014 and is headquartered in Wuxi, China. WuXi Biologics (Cayman) Inc. is a subsidiary of WuXi Biologics Holdings Limited.

Corporate governance

WuXi Biologics (Cayman) Inc.’s ISS governance QualityScore as of 1 May 2022 is 2. The pillar scores are Audit: 3; Board: 9; Shareholder rights: 2; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.